Diaverum

Fresenius Medical Care North America Announces New President for Renal Therapies Group

Thursday, July 22, 2021 - 6:00pm

WALTHAM, Mass., July 22, 2021 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products, announced today that Joseph (Joe) Turk has been named President for the company's Renal Therapies Group.

Key Points: 
  • WALTHAM, Mass., July 22, 2021 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products, announced today that Joseph (Joe) Turk has been named President for the company's Renal Therapies Group.
  • Turk succeeds Mark Costanzo, who recently retired as President of FMCNA's Renal Therapies Group.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.
  • Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent.

Fresenius Medical Care North America Names New Chief Medical Officer for Renal Therapies Group

Thursday, April 23, 2020 - 1:00pm

WALTHAM, Mass., April 23, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) today announced the appointment of Dr. Michael Anger as Senior Vice President and Chief Medical Officer for the company's Renal Therapies Group, the leading provider of kidney care products in North America.

Key Points: 
  • WALTHAM, Mass., April 23, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) today announced the appointment of Dr. Michael Anger as Senior Vice President and Chief Medical Officer for the company's Renal Therapies Group, the leading provider of kidney care products in North America.
  • Dr. Anger takes over the role from Dr. Robert Kossmann, who was promoted to Chief Medical Officer and Executive Vice President of FMCNA last year.
  • Dr.Angermost recently served as Chief Medical Officer of American Renal Associates, which operates dialysis clinics in 27 states and in Washington D.C. in partnership with about 400 nephrologists.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

Catasys Expands OnTrak-A Solution With Leading National Health Plan Into California

Tuesday, December 17, 2019 - 1:30pm

Catasys, Inc. (NASDAQ: CATS) (Catasys or the Company), a leading AI and technology-enabled healthcare company, today announced the expansion of its OnTrak-A solution with a leading national health plan into California beginning January 31, 2020.

Key Points: 
  • Catasys, Inc. (NASDAQ: CATS) (Catasys or the Company), a leading AI and technology-enabled healthcare company, today announced the expansion of its OnTrak-A solution with a leading national health plan into California beginning January 31, 2020.
  • This expansion ensures that eligible commercial members of the health plan in California will have access to critical behavioral healthcare to help them better manage chronic disease.
  • By combining predictive analytics with human engagement, Catasys delivers improved member health and validated outcomes and savings to healthcare payers.
  • OnTrak is available to members of leading national and regional health plans in 27 states.

U.S. Renal Care to Be Acquired by Investor Group

Wednesday, February 13, 2019 - 1:00pm

U.S. Renal Care, Inc., a leading provider of dialysis services for patients suffering from end stage renal disease, today announced that it has entered into a definitive agreement to be acquired by a private investor group led by Chris Brengard and the U.S. Renal management team, along with Bain Capital Private Equity, Summit Partners, Revelstoke Capital Partners, and Mark Caputo (collectively the Investor Group).

Key Points: 
  • U.S. Renal Care, Inc., a leading provider of dialysis services for patients suffering from end stage renal disease, today announced that it has entered into a definitive agreement to be acquired by a private investor group led by Chris Brengard and the U.S. Renal management team, along with Bain Capital Private Equity, Summit Partners, Revelstoke Capital Partners, and Mark Caputo (collectively the Investor Group).
  • U.S. Renal Care will continue to operate under its current management team, who will remain significant investors in the company.
  • Today, U.S. Renal Care serves approximately 25,000 patients in 335 dialysis facilities across 32 states and the Territory of Guam.
  • We are pleased to be partnering with an Investor Group that shares our commitment to serving patients and continuing to be the highest care provider by enhancing the quality of life for people living with chronic renal disease, said Chris Brengard, Chief Executive Officer of U.S. Renal Care.

Rockwell Medical Appoints VP, Strategic Accounts

Monday, October 1, 2018 - 1:00pm

WIXOM, Mich., Oct. 1, 2018 /PRNewswire/ --Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company" or "Rockwell Medical") today announced that Anne Boardman has been appointed Vice President, Strategic Accounts, effective today, October 1, 2018.

Key Points: 
  • WIXOM, Mich., Oct. 1, 2018 /PRNewswire/ --Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company" or "Rockwell Medical") today announced that Anne Boardman has been appointed Vice President, Strategic Accounts, effective today, October 1, 2018.
  • In recent years, Ms. Boardman served as VP, Strategic Accounts at Gambro Healthcare, and led the U.S. team responsible for contracting and deploying the full portfolio of Gambro products and therapies to support Dialysis clinics, in addition to managing numerous strategic customer relationships.
  • I am excited to work alongside Stuart and look forward to hitting the ground running and getting to know the rest of the Rockwell Medical team."
  • Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD).